Clinical Trials Logo

Clinical Trial Summary

Parkinson's disease (PD) is the second most common neurodegenerative disorder of the elderly that affects a million patients in US. Sleep dysfunction impacts up to 90% of PD patients. PD patients experience a variety of sleep disorders including parasomnias, specifically REM behavior disorder (RBD) that can precede the onset of motor manifestations of PD. RBD has negative consequences on patients' and their bed partners' quality of life mainly due to its impact on the sleep quality and day time alertness. RBD also predisposes affected individuals and their bed partners to physical injuries. There are no FDA approved treatments for RBD. Clonazepam is the most commonly used treatment but carries risks of daytime sedation, tolerance, and withdrawal symptoms. More recently, melatonin has been demonstrated to be effective in several small studies. Ramelteon, a selective melatonin receptor agonist with favorable safety profile, could potentially be effective for the treatment of RBD. This pilot protocol will investigate safety and efficacy of ramelteon for the treatment of RBD in subjects with parkinsonism. We plan to recruit 20 subjects with RBD diagnosed based on the clinical interview and confirmed by the polysomnographic (PSG) data. The study is designed as a prospective randomized placebo controlled 12-week study. Primary outcome measure will be change in frequency of RBD events based on the daily sleep diaries. Secondary outcome measure will be change in the amount of tonic muscle activity based on the results of the baseline and final PSG. A number of other secondary and exploratory outcome measures will be collected


Clinical Trial Description

See above. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00745030
Study type Interventional
Source Northwestern University
Contact
Status Terminated
Phase N/A
Start date June 2008
Completion date December 2009

See also
  Status Clinical Trial Phase
Recruiting NCT02194816 - Modifiable Variables in Parkinsonism (MVP)
Recruiting NCT04876326 - Potential Use of Autologous and Allogeneic Mesenchymal Stem Cells in Patients With Multiple System Atrophy N/A
Active, not recruiting NCT05127057 - Proactive and Integrated Management and Empowerment in Parkinson's Disease (PRIME-UK): A New Model of Care (PRIME-RCT) N/A
Enrolling by invitation NCT01453127 - DaTSCAN Imaging in Aging and Neurodegenerative Disease Phase 4
Completed NCT01174771 - Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration N/A
Completed NCT03314610 - Effect of Need to Void on Parkinsonian Gait
Recruiting NCT05506891 - Efficacy and Safety of Astragalus for Non-motor Symptoms of α-Synucleinopathy Phase 2
Completed NCT00950196 - Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia Phase 4
Recruiting NCT03924414 - Trial of Parkinson's And Zoledronic Acid Phase 4
Enrolling by invitation NCT05514106 - MIBG in Aging and Neurologic Disorders Phase 4
Completed NCT01581645 - Mobilaser Study to Help With People Who Are Having Problems With Their Gait Phase 0
Not yet recruiting NCT00767546 - Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients Phase 1
Completed NCT02214862 - 2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism Phase 0
Recruiting NCT04518059 - Misfolded Proteins in the Skin of People With Parkinson's Disease and Other Parkinsonism
Completed NCT03076671 - More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease N/A
Withdrawn NCT01329926 - Molecular Analysis of Human Neural Stem Cells
Completed NCT04222218 - Cerebellar rTMS Theta Burst for Postural Instability in Progressive Supranuclear Palsy N/A
Completed NCT03386669 - Novel Neuroimage Study in Tauopathies With Parkinsonism Phase 2
Completed NCT02064543 - Measurement of Gait Using Opal APDM and Gait Mat in Parkinsonism
Active, not recruiting NCT05308485 - Events Exposure as a Trigger of the Clinical Manifestations of Parkinson's Disease